Mood Stabilizers: Use, Drug Interactions, and Lithium Toxicity

Aims: This study aims to investigate the pharmacological management of Bipolar Affective Disorder (BAD) with a focus on lithium carbonate therapy, addressing the risks of toxicity, the role of polypharmacy, and the importance of patient adherence to treatment. The work also emphasizes the need for proper monitoring and education for patients undergoing lithium therapy in Psychosocial Care Centres (CAPS).

Methodology: A combination of clinical observations and laboratory tests, including the Osmotic Fragility Test, were conducted in CAPS facilities in Palmas (TO) and Mutuípe (BA) to assess the medications commonly used in the treatment of BAD. A review of literature and analysis of medication prescriptions were also incorporated to explore polypharmacy and medication interactions. Serum lithium levels and renal function were monitored to identify potential risks of toxicity.

Results: The study revealed that polypharmacy is prevalent in the treatment of BAD, with patients frequently prescribed lithium alongside other medications such as antipsychotics and antidepressants. Lithium toxicity was identified as a significant concern, with laboratory tests showing evidence of erythrocyte damage. Despite the efficacy of lithium in stabilizing mood and preventing relapses, the narrow therapeutic window necessitates careful monitoring. The study also highlighted the importance of multidisciplinary care and therapeutic workshops in improving patient adherence.

Conclusion: Lithium carbonate remains a cornerstone of BAD treatment, but its use requires vigilant monitoring to prevent toxicity and ensure therapeutic efficacy. Healthcare professionals must educate patients about the risks associated with lithium, emphasize adherence to prescribed regimens, and monitor closely for adverse reactions. Integrated care approaches, including psychotherapeutic interventions and family support, are essential for enhancing patients’ quality of life and supporting long-term psychiatric recovery. Further research is needed to optimize lithium therapy protocols and minimize risks associated with polypharmacy.